The OSCAR PUBLISHING Services
American Journal of Applied Science and Technology

VOLUME Vol.05 Issue01 2025
PAGE NO. 9-12
DOI 10.37547/ajast/Volume05Issue01-03

Review on the use of artificial intelligence to predict suitable drugs (AIPD)

[1]Nawras Yahya Hussein Al-Khafaji, [2]Sabreen Hassan Howaidy, [3]Zahraa Khawawm Abdulwahid
[123]College of Pharmacy, University of Babylon

Received: 16 November 2024; **Accepted:** 18 December 2024; **Published:** 08 January 2025

Abstract: Artificial intelligence and machine learning have revolutionized the pharmaceutical industry, offering new approaches to drug discovery and development. These techniques have the potential to improve the efficiency and accuracy of the drug discovery process, leading to the development of more effective medications.In particular, AI-based algorithms can be employed to predict the efficacy and toxicity of new drug compounds, as well as to identify new targets for drug development. This paper provides an overview of the current landscape of AI in large-molecule drug discovery, highlighting the increasing application of these techniques to areas such as antibodies, gene therapies, and RNA-based therapies. The paper also discusses the challenges and opportunities associated with the use of AI in pharmaceutical research and development, emphasizing the importance of balancing the promise of AI with a continued reliance on the scientific method. While the promise of AI in pharmaceutical research is significant, it is crucial to recognize the limitations of these technologies and to maintain a balanced approach that leverages the strengths of both AI-driven and traditional, scientific methods. By doing so, researchers and developers can harness the power of AI to accelerate the drug discovery process, while ensuring that the development of new drugs remains grounded in robust scientific principles.

Keywords: Artificial Intelligence, Machine Learning, Drug Discovery, Large Molecule Therapies, Pharmaceutical Research and Development.

Introduction: The Utilizing Artificial Intelligence for Drug Prediction The pharmaceutical industry has long relied on traditional methods of drug discovery, which are often time-consuming and inefficient. However, the rise of powerful statistical and biophysical modeling programs, as well as the growth of the field of bioinformatics, has led to the development of computational tools that can predict the properties of molecules with greater accuracy and efficiency. (Freedman, 2019) Artificial intelligence techniques, such as machine learning, are transforming the drug research and development process, enabled by the increasing availability of data and computational power. (Nagra et al., 2023),These AI-based approaches have the ability to improve the efficiency and accuracy of drug discovery processes, leading to the development of more effective medications. (Blanco-González et al., 2022) Some AI companies are focusing on the problem of designing a drug that can safely and effectively work on a known target, usually a specific, well-studied protein that is associated with a particular disease. (Freedman, 2019) ,Predicting Binding Interactions with AI-Bind One such AI-based tool is AI-Bind, which offers a powerful high-throughput approach to identify drug-target combinations. The accurate prediction of binding interactions between chemicals and proteins is a critical step in drug discovery, as it helps to identify new drugs and novel therapeutic targets, reduce the failure rate in clinical trials, and predict the safety of drugs. (Chatterjee et al., 2021),AI-Bind utilizes machine learning algorithms to predict protein-ligand binding interactions, and the predictions are validated through docking simulations and comparison with recent experimental evidence. The tool also helps to identify potential active binding sites on the amino acid sequence, providing valuable insights into the interpretation of machine learning predictions of protein-ligand binding,. (Chatterjee et al., 2021),Expanding the Scope of Drug Discovery with AI While traditional methods of pharmaceutical

research have been relatively successful in the past, they are limited by their reliance on trial-and-error experimentation and their inability to accurately predict the behavior of new potential bioactive compounds,. (Blanco-González et al., 2022) AI-based approaches, on the other hand, have the ability to expand the scope of drug discovery beyond the limitations of more conventional approaches, potentially leading to the development of novel and more effective medications (Blanco-González et al., 2022).

AI-Driven Approach to Identifying Appropriate Drugs

The rise of artificial intelligence techniques, such as machine learning and bioinformatics, has transformed the landscape of drug research and development. These AI-based methods offer a powerful approach to identify drug-target combinations, with the potential to become a valuable tool in drug discovery. (Chatterjee et al., 2021) ,One key advantage of AI-driven drug discovery is its ability to accurately predict binding interactions between chemicals and proteins, a critical step in identifying new drugs and therapeutic targets. (Chatterjee et al., 2021) Tools like AI-Bind utilize machine learning algorithms to predict protein-ligand binding, and validate these predictions through docking simulations and experimental evidence. (Chatterjee et al., 2021),Beyond binding prediction, AI-based approaches also have the potential to expand the scope of drug discovery. Traditional pharmaceutical research methods are often limited by their reliance on trial-and-error experimentation and their inability to accurately predict the behavior of new bioactive compounds. (Blanco-González et al., 2022) ,In contrast, AI-driven techniques can identify new drug targets, such as specific proteins or genetic pathways involved in diseases, and can lead to the development of novel and more effective medications. (Blanco-González et al., 2022),"The pharmaceutical industry is increasingly adopting AI-based tools to improve the efficiency and accuracy of drug discovery processes. As the availability of data and computational power continues to grow, the role of artificial intelligence in drug research and development is expected to become even more prominent. (Nagra et al., 2023).

Artificial Intelligence: A Tool for Drug Suitability Prediction

The pharmaceutical industry has long faced challenges in the drug discovery process, often relying on time-consuming and inefficient traditional methods. However, the rise of artificial intelligence techniques, such as machine learning and bioinformatics, has the potential to transform this landscape. (Freedman, 2019)(Hasselgren & Oprea, 2023) , One key advantage of AI-driven drug discovery is its ability to accurately predict binding interactions between chemicals and proteins, a critical step in identifying new drugs and therapeutic targets. (Chatterjee et al., 2021) Tools like AI-Bind utilize machine learning algorithms to predict protein-ligand binding, and validate these predictions through docking simulations and experimental evidence. (Chatterjee et al., 2021) ,Beyond binding prediction, AI-based approaches also have the potential to expand the scope of drug discovery. Traditional pharmaceutical research methods are often limited by their reliance on trial-and-error experimentation and their inability to accurately predict the behavior of new bioactive compounds. (Blanco-González et al., 2022) ,In contrast, AI-driven techniques can identify new drug targets, such as specific proteins or genetic pathways involved in diseases, and can lead to the development of novel and more effective medications. (Blanco-González et al., 2022),The pharmaceutical industry is increasingly adopting AI-based tools to improve the efficiency and accuracy of drug discovery processes. As the availability of data and computational power continues to grow, the role of artificial intelligence in drug research and development is expected to become even more prominent. ,Overall, the integration of AI into the drug discovery pipeline holds significant promise.

AI-Enabled Drug Suitability Forecasting

The pharmaceutical industry has long faced challenges in the drug discovery process, often relying on time-consuming and inefficient traditional methods. However, the rise of artificial intelligence techniques, such as machine learning and bioinformatics, has the potential to transform this landscape. (Freedman, 2019) (Hasselgren & Oprea, 2023) ,One key advantage of AI-driven drug discovery is its ability to accurately predict binding interactions between chemicals and proteins, a critical step in identifying new drugs and therapeutic targets. (Chatterjee et al., 2021) ,Tools like AI-Bind utilize machine learning algorithms to predict protein-ligand binding, and validate these predictions through docking simulations and experimental evidence. (Chatterjee et al., 2021) ,Beyond binding prediction, AI-based approaches also have the potential to expand the scope of drug discovery. Traditional pharmaceutical research methods are often limited by their reliance on trial-and-error experimentation and their inability to accurately predict the behavior of new bioactive compounds. (Blanco-González et al., 2022) ,In contrast, AI-driven techniques can identify new drug targets, such as specific proteins or genetic pathways involved in diseases, and can lead to the development of novel and more effective medications. (Blanco-González et al.,

2022),The pharmaceutical industry is increasingly adopting AI-based tools to improve the efficiency and accuracy of drug discovery processes. As the availability of data and computational power continues to grow, the role of artificial intelligence in drug research and development is expected to become even more prominent. (Nagra et al., 2023),Overall, the integration of AI into the drug discovery pipeline holds significant promise and could lead to the development of more effective and safer medications.

Harnessing the Power of AI for Optimal Drug Selection

The pharmaceutical industry has long faced challenges in the drug discovery process, often relying on time-consuming and inefficient traditional methods. However, the rise of artificial intelligence techniques, such as machine learning and bioinformatics, has the potential to transform this landscape. (Freedman, 2019) (Hasselgren & Oprea, 2023) ,One key advantage of AI-driven drug discovery is its ability to accurately predict binding interactions between chemicals and proteins, a critical step in identifying new drugs and therapeutic targets. (Chatterjee et al., 2021) ,Tools like AI-Bind utilize machine learning algorithms to predict protein-ligand binding, and validate these predictions through docking simulations and experimental evidence. (Chatterjee et al., 2021) ,Beyond binding prediction, AI-based approaches also have the potential to expand the scope of drug discovery. Traditional pharmaceutical research methods are often limited by their reliance on trial-and-error experimentation and their inability to accurately predict the behavior of new bioactive compounds. (Blanco-González et al., 2022) ,In contrast, AI-driven techniques can identify new drug targets, such as specific proteins or genetic pathways involved in diseases, and can lead to the development of novel and more effective medications. (Blanco-González et al., 2022),The pharmaceutical industry is increasingly adopting AI-based tools to improve the efficiency and accuracy of drug discovery processes. As the availability of data and computational power continues to grow, the role of artificial intelligence in drug research and development is expected to become even more prominent. (Nagra et al., 2023),Overall, the integration of AI into the drug discovery pipeline holds significant promise and could lead to the development of more effective and safer medications.While the potential of AI in drug discovery is evident, there are also challenges that must be addressed. The scientific community must carefully vet known information to address the reproducibility crisis, and ensure that AI-derived insights are backed by robust experimental validation. (Hasselgren & Oprea, 2023) Additionally, human intervention and expertise remain crucial at later stages of the drug discovery pipeline, as AI tools cannot fully replace the complexity of the systematic scientific process. (Hasselgren & Oprea, 2023) (Maria et al., 2023) ,By judiciously applying AI techniques and maintaining appropriate human oversight, the pharmaceutical industry can leverage the power of artificial intelligence to predict suitable drug candidates more accurately and efficiently, ultimately leading to the development of more effective and safer medications.

Balancing AI and Human Expertise in Drug Discovery

The integration of artificial intelligence into the drug discovery process holds significant promise, as AI-driven techniques have the potential to improve the efficiency and accuracy of identifying suitable drug candidates. One key advantage of AI-powered drug discovery is its ability to predict binding interactions between chemicals and proteins, a crucial step in the identification of new drugs and therapeutic targets. (Chatterjee et al., 2021) Tools like AI-Bind utilize machine learning algorithms to predict protein-ligand binding and validate these predictions through docking simulations and experimental evidence. (Chatterjee et al., 2021) , Beyond binding prediction, AI-based approaches can also expand the scope of drug discovery, as they have the potential to identify new drug targets, such as specific proteins or genetic pathways involved in diseases, which may lead to the development of novel and more effective medications. (Blanco-González et al., 2022) ,The pharmaceutical industry is increasingly adopting AI-based tools to leverage the growing availability of data and computational power, and the role of artificial intelligence in drug research and development is expected to become even more prominent. (Nagra et al., 2023) ,However, it is important to note that the integration of AI into the drug discovery pipeline is not without its challenges. The scientific community must carefully vet known information to address the reproducibility crisis, and ensure that AI-derived insights are backed by robust experimental validation. (Hasselgren & Oprea, 2023) ,Additionally, human intervention and expertise remain crucial at later stages of the drug discovery pipeline, as AI tools cannot fully replace the complexity of the systematic scientific process. (Hasselgren & Oprea, 2023) (Maria et al., 2023) ,By judiciously applying AI techniques and maintaining appropriate human oversight, the pharmaceutical industry can leverage the power of artificial intelligence to predict suitable drug candidates more accurately and efficiently, ultimately leading to the development of more effective and safer medications. As the availability of data and computational power continues to grow, the

pharmaceutical industry is increasingly adopting AI-based tools to streamline the drug discovery process. (Nagra et al., 2023),While the potential of AI in drug discovery is evident, there are also challenges that must be addressed. The scientific community must carefully vet known information to address the reproducibility crisis, and ensure that AI-derived insights are backed by robust experimental validation. (Hasselgren & Oprea, 2023) Additionally, human intervention and expertise remain crucial at later stages of the drug discovery pipeline, as AI tools cannot fully replace the complexity of the systematic scientific process. (Hasselgren & Oprea, 2023) (Maria et al., 2023) By judiciously applying AI techniques and maintaining appropriate human oversight, the pharmaceutical industry can leverage the power of artificial intelligence to predict suitable drug candidates more accurately and efficiently, ultimately leading to the development of more effective and safer medications.

Conclusion

Artificial intelligence has revolutionized the field of drug discovery, offering a more efficient and accurate approach to identifying potential drug candidates AI-based algorithms can predict the efficacy and toxicity of new drug compounds with greater accuracy than traditional methods , and can also be used to identify new drug targets, such as specific proteins or genetic pathways involved in diseases AI tools tackle different aspects of drug discovery, from modeling small-molecule-target interactions to lead candidate optimization and safety prediction, While traditional drug discovery methods have been successful in the past, they are limited by their reliance on trial-and-error experimentation and their inability to accurately predict the behavior of new potential bioactive compounds . AI-based approaches, on the other hand, have the ability to improve the efficiency and accuracy of drug discovery processes, ultimately leading to the development of more effective medications However, it is important to recognize that the scientific method is not obsolete when making inferences about data, and that separating hope from hype is crucial in ensuring the optimal use of AI/ML in drug development , the use of artificial intelligence in drug discovery has immense potential, but it must be balanced with a careful consideration of the limitations and challenges associated with this technology.

References

1. Blanco-González, A., Cabezon, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & García-Fandiño, R. (2022). The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. In A. Blanco-González, A. Cabezon, A. Seco-González, D. Conde-Torres, P. Antelo-Riveiro, Á. Piñeiro, & R. García-Fandiño, arXiv (Cornell University). Cornell University. https://doi.org/10.48550/arxiv.2212.08104

2. Chatterjee, A., Walters, R., Shafi, Z., Ahmed, O. S., Šebek, M., Gysi, D. M., Yu, R., Eliassi-Rad, T., Barabási, A., & Menichetti, G. (2021). AI-Bind: Improving Binding Predictions for Novel Protein Targets and Ligands. In A. Chatterjee, R. Walters, Z. Shafi, O. S. Ahmed, M. Šebek, D. M. Gysi, R. Yu, T. Eliassi-Rad, A. Barabási, & G. Menichetti, arXiv (Cornell University). Cornell University. https://doi.org/10.48550/arxiv.2112.13168

3. Freedman, D. H. (2019). Hunting for New Drugs with AI. In D. H. Freedman, Nature (Vol. 576, Issue 7787). Nature Portfolio. https://doi.org/10.1038/d41586-019-03846-0

4. Hasselgren, C., & Oprea, T. I. (2023). Artificial Intelligence for Drug Discovery: Are We There Yet? [Review of Artificial Intelligence for Drug Discovery: Are We There Yet?]. The Annual Review of Pharmacology and Toxicology, 64(1), 527. Annual Reviews. https://doi.org/10.1146/annurev-pharmtox-040323-040828

5. Maria, J. P. S., Wang, Y., & Camargo, L. M. (2023). Perspective on the challenges and opportunities of accelerating drug discovery with artificial intelligence. In J. P. S. Maria, Y. Wang, & L. M. Camargo, Frontiers in Bioinformatics (Vol. 3). Frontiers Media. https://doi.org/10.3389/fbinf.2023.1121591

6. Nagra, N. S., Veken, L. van der, Stanzl, E. G., Champagne, D. W., Devereson, A., & Macak, M. (2023). The company landscape for artificial intelligence in large-molecule drug discovery [Review of The company landscape for artificial intelligence in large-molecule drug discovery]. Nature Reviews Drug Discovery, 22(12), 949. Nature Portfolio. https://doi.org/10.1038/d41573-023-00139-0/doi.org/10.1016/j.jchas.2006.11.001